Glycogen-rich mesothelioma

Ultrastructural Pathology

Volumn 23, Issue 6, 1999, Pages 401-406

  Ordóñez, Nelson G ^a   Mackay, Bruce ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Electron microscopy; Glycogen; Immunohistochemistry; Mesothelioma

Indexed keywords

GLYCOGEN;

AGED; ARTICLE; CASE REPORT; CELL ULTRASTRUCTURE; CLEAR CELL CARCINOMA; ELECTRON MICROSCOPY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; PRIORITY JOURNAL;

EID: 0033386649     PISSN: 01913123     EISSN: None     Source Type: Journal    
DOI: 10.1080/019131299281383     Document Type: Article

References (44)

1. 1. Mayall FG, Gibbs AR. The histology and immunohistochemistry of small cell mesothelioma. Histopathology. 1992;20:47-51.
2. 2. Nascimento AG, Keeney GL, Fletcher CDM. Deciduoid peritoneal mesothelioma: an unusual phenotype affecting young females. Am J Surg Pathol. 1994;18:439-445.
3. 3. Ordóñez NG, Myhre M, Mackay B. Clear cell mesothelioma. Ultrastruct Pathol. 1996;20:331-336.
4. 4. Orosz Z, Nagy P, Szentirmay Z, Zalatnai A, Hauser P. Epithelial mesothelioma with deciduoid features. Virchows Arch. 1999;434:263-266.
5. 5. Miller K, Auld J, Jessup E, Rhodes A, Ashton-Key M. Antigen unmasking in formalin-fixed routinely processed paraffin wax-embedded sections by pressure cooking: a comparison with microwave oven heating and traditional methods. Adv Anatomic Pathol. 1995;2:60-64.
6. 6. Civantos F, Albores-Saavedra J, Nadji M, Morales AR. Clear cell variant of thyroid carcinoma. Am J Surg Pathol. 1984;8:187-192.
7. 7. Guarda LA, Silva EG, Ordóñez NG, Mackay B, Ibanez ML. Clear cell islet cell tumor. Am J Clin Pathol. 1983;79:512-517.
8. 8. Mackay B, Ordóñez NG, Khoursand J, Bennington JL. The ultrastructure and immunocytochemistry of renal cell carcinoma. Ultrastruct Pathol. 1987;11:483-502.
9. 9. Mackay B, Lukeman JM, Ordóñez NG. Tumors of the Lung. Philadelphia. Saunders: 1991:323-364.
10. 10. Ordóñez NG, Mackay B, El-Naggar A, Bannayan GA, Duncan J. Clear cell carcinoid tumor of the stomach. Histopathology. 1993;22:190-193.
11. 11. Silva EG, Mackay B, Samaan NA, Hickey RC. Adrenocortical carcinomas: an ultrastructural study of 22 cases. Ultrastruct Pathol. 1982;3:1-7.
12. 12. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 1989;13:276-291.
13. 13. Ordóñez NG. Value of antibodies 44-3A6, SM3, HBME-1 and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Am J Surg Pathol. 1997;21:1399-1408.
14. 14. Riera JR, Astengo-Osuna C, Longmate JA, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation following heat-induced epitope retrieval. Am J Surg Pathol. 1997;21:1409-1419.
15. 15. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol. 1996;20:1037-1046.
16. 16. Ordóñez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol. 1998;11:929-933.
17. 17. Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology. 1997;31:140-143.
18. 18. Ordóñez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol. 1998;22:1215-1221.
19. 19. Collins CL, Ordóñez NG, Schaefer R, et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol. 1992;141:827-833.
20. 20. Ordóñez NG. Value of thrombomodulin immunostaining in the diagnosis of mesothelioma. Histopathology. 1997;31:25-30.
21. 21. Andressen C, Blumcke I, Celio MR. Calcium-binding proteins: selective markers of nerve cells. Cell Tissue Res. 1993;271:181-208.
22. 22. Moll R, Dhouailly D, Sun T-T. Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas: an immunohistochemical study using monoclonal antibody AE14. Virchows Archiv B Cell Pathol. 1989;58:129-145.
23. 23. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989;264:4743-4746.
24. 24. Jackson DE, Mitchell CA, Bird P, Salem HH, Hayman JA. Immunohistochemical localization of thrombomodulin in normal skin and skin tumours. J Pathol. 1995;175:421-432.
25. 25. Maruyama I, Bell C, Majerus P. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblasts of human placenta. J Cell Biol. 1985;101:363-371.
26. 26. Ordóñez NG. Thrombomodulin expression in transitional cell carcinoma. Am J Clin Pathol. 1998;110:385-390.
27. 27. Brown RW, Clark GM, Tandon AK, Allred DC. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol. 1993;24:347-354.
28. 28. Ascoli V, Scalzo CC, Taccogna S, Mardi F. The diagnostic value of thrombomodulin immunolocalization in serous effusions. Arch Pathol Lab Med. 1995;119:1136-1140.
29. 29. Attanoos RL, Goddard H, Gibbs AR. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma. Histopathology. 1996;29:209-215.
30. 30. Kennedy AD, King G, Kerr KM. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. J Clin Pathol. 1997;50:859-862.
31. 31. Ordóñez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol. 1998;22:1203-1214.
32. 32. Miettinen M, Kovatich AJ. HBME-1 - A monoclonal antibody useful in the differential diagnosis of mesothelioma, adenocarcinoma, and soft tissue and bone tumors. Appl Immunohistochem. 1995;3:115-122.
33. 33. Bateman AC, Al-Talib RK, Newman T, Williams JH, Herbert A. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Histopathology. 1997;30:49-56.
34. 34. Ruitenbeek T, Gouw ASH, Poppema S. Immunocytology of body cavity fluids: MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. Arch Pathol Lab Med. 1994;118:265-269.
35. 35. Ordóñez NG. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol. 1998;29:166-169.
36. 36. Sosolik RC, McGaughy VR, De Young BR. Anti-MOC-31 : a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel. Mod Pathol 1997;10:716-719
37. y, in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Am J Pathol 1989;135:931-937
38. 38. De Leij L, Broers J, Ramaekers F, Berendsen H, Wagenaar SJSC. Monoclonal antibodies in clinical and experimental pathology of lung cancer. In: Ruiter DJ, Fleuren GJ, Warnaar SO, eds. Application of Monoclomal Antibodies in Tumor Pathology. Dordrecht: Martinus Nijhoff Publishers, 1987:191-210.
39. 39. De Leij L, Helrich W, Stein R, Mattes MJ. SCLC-cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EG P-2. Int J Cancer Supplement 1994;8:60-63.
40. 40. Edwards C, Dates J. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin-fixed and paraffin wax embedded material. J Clin Pathol 1995;48:626-630.
41. 41. Han AC, Peralta-Soler A, Knudsen KA, Wheelock MJ, Johnson KR, Salazar H. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues. Hum Pathol 1997;28:641-645.
42. 42. Leers MPG, Aarts MMJ, Theunissen PHMH. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998;32:209-216.
43. 43. Amin KM, Litzky LA, Smythe WR, et al. Wilms' tumor 1 susceptibility (WT1 ) gene products are selectively expressed in malignent mesothelioma. Am J Pathol 1995;146:344-356.
44. 44. Kumar-Singh S, Segers K, Rodeck U, et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol. 1997;181:67-74.